Genelux Corporation Common Stock (GNLX)

About GNLX

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discover…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

25

Website

genelux.com/

Fundamentals

1-day range

$2.65$2.87

Market cap

$121.07M

P/E (trailing)

—

P/E (forward)

-3.67

EPS (trailing)

$-0.85

Dividend yield

—

Beta

0.54

Avg. volume

242.5K

Forecasts

6 analyst ratings

Genelux Corporation Common Stock Competitors

Chosen by industry and closest market cap.

• GNLX

  Genelux Corporation Common Stock

  $2.66

  ▼ 7.64%
  Market cap $121.07MP/E —
  $2.29$8.54
• PMN

  ProMIS Neurosciences Inc. Common Shares (ON)

  $13.79

  ▼ 1.43%
  Market cap $119.54MP/E —
  $6.27$27.4
• BGM

  BGM Group Ltd. Class A Ordinary Shares

  $0.3251

  ▲ 11.34%
  Market cap $118.62MP/E —
  $0.2287$11.8
• IFRX

  InflaRx N.V. Common Stock

  $2.22

  ▼ 2.20%
  Market cap $124.34MP/E —
  $0.7984$2.95
• SPRB

  Spruce Biosciences Inc. Common Stock

  $60.05

  ▼ 5.13%
  Market cap $127.76MP/E —
  $7$240
• NRXP

  NRX Pharmaceuticals Inc. Common Stock

  $3.54

  ▼ 2.21%
  Market cap $111.95MP/E —
• PLYX

  Polaryx Therapeutics Inc. Common Stock

  $2.07

  ▼ 2.13%
  Market cap $110.66MP/E —
  $1.86$48.91

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate
  Benzinga · 8/13/2026

• Yu Yong · August 4, 2026 · Sale

  653 @ $2.94
• Joseph Cappello · August 4, 2026 · Sale

  653 @ $2.95
• Thomas Zindrick · August 4, 2026 · Sale

  3.0K @ $2.95
• John W. Smither · July 1, 2026 · Sale

  12.0K @ $2.91
• Matthew Pulisic · June 16, 2026 · Grant

  278.9K
• Eric Groen · June 16, 2026 · Grant

  234.0K
• Joseph Cappello · June 16, 2026 · Grant

  174.8K
• James L. Tyree · June 16, 2026 · Grant

  31.6K
• James L. Tyree · June 16, 2026 · Grant

  28.4K
• Thomas Zindrick · June 16, 2026 · Grant

  730.6K
• John Thomas · June 16, 2026 · Grant

  31.6K
• John Thomas · June 16, 2026 · Grant

  28.4K
• Mary Mirabelli · June 16, 2026 · Grant

  31.6K
• Mary Mirabelli · June 16, 2026 · Grant

  28.4K
• Yu Yong · June 16, 2026 · Grant

  119.3K

Institutional Ownership

March 31, 2026

Total shares held

9.04M

Total value held

$22.65M

Institutional holders

68